Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations

Analysts at Canaccord Genuity initiated coverage on shares of Mast Therapeutics (NYSE: MSTX) with a “buy” rating. The target price for Mast Therapeutics is set to $3. Mast Therapeutics' shares closed at $0.45 yesterday.

Bank of America initiated coverage on shares of NPS Pharmaceuticals (NASDAQ: NPSP) with a “buy” rating. The target price for NPS Pharmaceuticals is set to $46. NPS Pharmaceuticals' shares closed at $33.39 yesterday.

Wunderlich initiated coverage on shares of Regions Financial (NYSE: RF) with a “buy” rating. The target price for Regions Financial is set to $12. Regions Financial's stock closed at $9.33 yesterday.

Analysts at Cowen & Company initiated coverage on shares of Orexigen Therapeutics (NASDAQ: OREX) with an “outperform” rating. The target price for Orexigen Therapeutics is set to $10. Orexigen Therapeutics' shares closed at $6.06 yesterday.

Latest Ratings for MSTX

DateFirmActionFromTo
Sep 2016DowngradesOutperformMarket Perform
Nov 2015Initiates Coverage onBuy
Apr 2015Initiates Coverage onBuy

View More Analyst Ratings for MSTX
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (NPSP + MSTX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
XLNXCascendUpgrades115.0
CISNBairdDowngrades10.0
WDAYSociete GeneraleUpgrades
BKUDA DavidsonInitiates Coverage On39.0
JDVertical GroupInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Cracker Barrel Sends Proxy Materials for Annual Meeting, Urges Rejection of Biglari Nominations, Proposal on $20/Share Special Dividend

Lilly Reaffirms Outlook, Will Buyback Up to $5B in Shares, Maintaining Dividend